Download PDF
Radiologie up2date 2024; 24(04): 341-359
DOI: 10.1055/a-2339-8420
Neuroradiologie

Zerebrale Amyloidangiopathie und ihre Folgen

Cerebral amyloid angiopathy and its consequences
Stefan Weidauer 
› Further Information
Also available at
    Permissions and Reprints All articles of this category

Die zerebrale Amyloidangiopathie (CAA) ist charakterisiert durch Amyloidablagerungen in kleinen kortikalen und leptomeningealen Gefäßen, wobei die Boston-Kriterien die Diagnosestellung einer wahrscheinlichen CAA ermöglichen. Bei der CAA-assoziierten Inflammation treten amyloidbedingte bildmorphologische Auffälligkeiten auf, bei denen ein ödematöser und ein hämorrhagischer Subtyp in der MRT unterschieden werden können.

Abstract

Cerebral amyloid angiopathy (CAA) is characterized by the deposition of amyloid in the vessel walls of small cortical and leptomeningeal arteries. Whereas the definite diagnosis requires a brain biopsy, knowledge of clinical and neuroimaging findings in CAA is essential. The Boston criteria version 2.0 including characteristic clinical and neuroradiological features facilitates the diagnosis of probable CAA. Spontaneous and amyloid-beta immunotherapy-associated CAA-related inflammation cause amyloid related imaging abnormalities (ARIA). There are two subtypes: ARIA-E (edema, leptomeningeal effusion) and ARIA-H (haemorrhagic).

Kernaussagen

  • Die CAA ist charakterisiert durch Amyloidablagerungen in kleinen kortikalen und leptomeningealen Gefäßen.

  • Die Prävalenz der CAA steigt mit dem Alter und beträgt bei kognitiv Beeinträchtigten über 80 Jahre 50–60%.

  • Häufige Manifestation ist die spontane lobare intrazerebrale Blutung (ICB) mit hohem Rezidivrisiko.

  • Neurologisch typisch sind transiente fokale neurologische Episoden (TFNE) und zunehmende kognitive Ausfälle bis hin zur Demenz vom Alzheimer-Typ.

  • Charakteristische neuroradiologische Befunde sind:

    • lobare ICB

    • kortikale/subkortikale Mikroblutungen (MB)

    • kortikale Subarachnoidalblutung (SAB)

    • kortikale superfizielle Siderose (SS)

    • erweiterte perivaskuläre Räume und T2-hyperintense Läsionen im Centrum semiovale

  • Hämosensitive MRT-Sequenzen (T2*, besser SWI) sind essenziell.

  • Die Boston-Kriterien Version 2.0 erleichtern die klinische Diagnosestellung.

  • Die CAA-assoziierte Inflammation (CAA-ai) entspricht dem Subtyp mit 2 Varianten von ARIA: vasogenes Ödem und leptomeningeale Effusionen (ARIA-E) und hämorrhagische Läsionen (ARIA-H).

  • ARIA treten bei ca. 20% von Patienten mit monoklonaler Antikörpertherapie gegen Amyloid-β (Aβ) auf.

Schlüsselwörter

zerebrale Amyloidangiopathie (CAA) - Boston-Kriterien - amyloidbedingte bildmorphologische Auffälligkeiten (ARIA)

Keywords

cerebral amyloid angiopathy (CAA) - Boston criteria - amyloid related imaging abnormalities (ARIA)


Publication History

Article published online:
06 December 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revis-ited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry 2012; 83: 124-137
    CrossrefPubMedSearch in Google Scholar
  • 2 Greenberg SM, Vonsattel JP, Stakes JW. et al. The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology 1993; 43: 2073-2079
    CrossrefPubMedSearch in Google Scholar
  • 3 Greenberg SM, Bacskai BJ, Hernandez-Guillamon M. et al. Cerebral amyloid angiopathy and Alzheimer disease—one peptide, two pathways. Nat Rev Neurol 2020; 16: 30-42
    CrossrefPubMedSearch in Google Scholar
  • 4 Weller RO, Subash M, Preston SD. et al. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol 2008; 18: 253-266
    CrossrefPubMedSearch in Google Scholar
  • 5 Weller RO, Hawkes CA, Kalaria RN. et al. White Matter Changes in Dementia: Role of Impaired Drainage of Interstitial Fluid. Brain Pathol 2015; 25: 63-78
    CrossrefPubMedSearch in Google Scholar
  • 6 Benveniste H, Liu X, Koundal S. et al. The Glymphatic System and Waste Clearance with Brain Aging: A Review. Gerontology 2019; 65: 106-119
    CrossrefPubMedSearch in Google Scholar
  • 7 Cozza M, Amadori L, Boccardi V. Exploring cerebral amyloid angiopathy: Insights into pathogenesis, diagnosis, and treatment. J Neurol Sci 2023; 454: 120866
    CrossrefPubMedSearch in Google Scholar
  • 8 Jäkel L, De Kort AM, Klijn CJM. et al. Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. Alzheimers Dement 2022; 18: 10-28
    CrossrefPubMedSearch in Google Scholar
  • 9 Charidimou A. Cerebral amyloid angiopathy-related transient focal neurological episodes (CAA-TFNEs): A well-defined clinical-radiological syndrome. J Neurol Sci 2019; 406: 116496
    CrossrefPubMedSearch in Google Scholar
  • 10 Weidauer S, Tafreshi M, Foerch C. et al. Clinical and neuroimaging precursors in cerebral amyloid angiopathy: Impact of the Boston criteria version 2.0. Eur J Neurol 2024; 10: e16425
    CrossrefPubMedSearch in Google Scholar
  • 11 Charidimou A, Boulouis G, Frosch MP. et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol 2022; 21: 714-725
    CrossrefPubMedSearch in Google Scholar
  • 12 Greenberg SM, Vernooij MW, Cordonnier C. Microbleed Study Group. et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009; 8: 165-174
    CrossrefPubMedSearch in Google Scholar
  • 13 Haller S, Vernooij MW, Kuijer JPA. et al. Cerebral microbleeds: imaging and clinical significance. Radiology 2018; 287: 11-28
    CrossrefPubMedSearch in Google Scholar
  • 14 Wardlaw JM, Smith EE, Biessels GJ. STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12: 822-838
    CrossrefPubMedSearch in Google Scholar
  • 15 Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9: 689-701
    CrossrefPubMedSearch in Google Scholar
  • 16 Weidauer S, Wagner M, Hattingen E. White Matter Lesions in Adults – a Differential Diagnostic Approach. Rofo 2020; 192: 1154-1173
    Thieme ConnectPubMedSearch in Google Scholar
  • 17 Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston criteria. Stroke 2018; 49: 491-497
    CrossrefPubMedSearch in Google Scholar
  • 18 Linn J. Zerebrale Mikroblutungen: Bildgebung, Ursachen und Differenzialdiagnosen. Radiologie up2date 2016; 16: 279-292
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Charidimou A, Boulouis G, Fotiadis P. et al. Acute convexity subarachnoid haemorrhage and cortical superficial siderosis in probable cerebral amyloid angiopathy without lobar haemorrhage. J Neurol Neurosurg Psychiatry 2018; 89: 397-403
    CrossrefPubMedSearch in Google Scholar
  • 20 Charidimou A, Linn J, Vernooij MW. et al. Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions. Brain 2015; 138: 2126-2139
    CrossrefPubMedSearch in Google Scholar
  • 21 Kumar N. Superficial Siderosis: A clinical review. Ann Neurol 2021; 89: 1068-1079
    CrossrefPubMedSearch in Google Scholar
  • 22 Weidauer S, Neuhaus E, Hattingen E. Cerebral Superficial Siderosis: Etiology, Neuroradiological Features and Clinical Findings. Clin Neuroradiol 2023; 33: 293-306
    CrossrefPubMedSearch in Google Scholar
  • 23 Linn J, Halpin A, Demaerel P. et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010; 74: 1346-1350
    CrossrefPubMedSearch in Google Scholar
  • 24 Linn J, Michl S, Katja B. et al. Cortical vein thrombosis: the diagnostic value of different imaging modalities. Neuroradiology 2010; 52: 899-911
    CrossrefPubMedSearch in Google Scholar
  • 25 Charidimou A, Boulouis G, Pasi M. et al. MRI-visible perivascular spaces in cerebral amyloid angiopathy and hypertensive arteriopathy. Neurology 2017; 88: 1157-1164
    CrossrefPubMedSearch in Google Scholar
  • 26 Charidimou A, Boulouis G, Haley K. et al. White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy. Neurology 2016; 86: 505-511
    CrossrefPubMedSearch in Google Scholar
  • 27 Knudsen KA, Rosand J, Karluk D. et al. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001; 56: 537-539
    CrossrefPubMedSearch in Google Scholar
  • 28 Caetano A, Ladeira F, Barbosa R. et al. Cerebral amyloid angiopathy – The modified Boston criteria in clinical practice. J Neurol Sci 2018; 384: 55-57
    CrossrefPubMedSearch in Google Scholar
  • 29 Charidimou A, Boulouis G. Clinical Diagnosis of Probable Cerebral Amyloid Angiopathy: Diagnostic Accuracy Meta-Analysis of the Boston Criteria. Stroke 2022; 53: 3679-3687
    CrossrefPubMedSearch in Google Scholar
  • 30 Stehling C, Wersching H, Kloska SP. et al. Detection of asymptomatic cerebral microbleeds: a comparative study at 1.5 and 3.0 T. Acad Radiol 2008; 15: 895-900
    CrossrefPubMedSearch in Google Scholar
  • 31 Cheng AL, Batool S, McCreary CR. et al. Susceptibility-weighted imaging is more reliable than T2*- weighted gradient-recalled echo MRI for detecting microbleeds. Stroke 2013; 44: 2782-2786
    CrossrefPubMedSearch in Google Scholar
  • 32 Salvarani C, Hunder GG, Morris JM. et al. Aβ-related angiitis: comparison with CAA without inflammation and primary CNS vasculitis. Neurology 2013; 81: 1596-1603
    CrossrefPubMedSearch in Google Scholar
  • 33 Auriel E, Charidimou A, Gurol ME. et al. Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation. JAMA Neurol 2016; 73: 197-202
    CrossrefPubMedSearch in Google Scholar
  • 34 Antolini L, Di Francesco JC, Zedde M. et al. Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study. Neurology 2021; 97: e1809-e1822
    CrossrefPubMedSearch in Google Scholar
  • 35 Coulette S, Renard D, Lehmann S. et al. A clinico-radiological study of cerebral amyloid angiopathy–related inflammation. Cerebrovasc Dis 2019; 48: 38-44
    CrossrefPubMedSearch in Google Scholar
  • 36 Barakos J, Sperling R, Salloway S. et al. MR imaging features of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol 2013; 34: 1958-1965
    CrossrefPubMedSearch in Google Scholar
  • 37 Barkhof F, Daams M, Scheltens P. et al. An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion. AJNR Am J Neuroradiol 2013; 34: 1550-1555
    CrossrefPubMedSearch in Google Scholar
  • 38 Urbach H, Linn J, Hattingen E. et al. Imaging of Amyloid-Related Imaging Abnormalities (ARIA). Rofo 2024; 196: 363-369
    Thieme ConnectPubMedSearch in Google Scholar
  • 39 Schaumberg J, Trauscheid M, Eckert B. et al. Cerebral amyloid angiopathy associated with inflammation. Nervenarzt 2018; 89: 682-691
    CrossrefPubMedSearch in Google Scholar
  • 40 Scolding NJ, Joseph F, Kirby PA. et al. Aβ-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005; 128: 500-515
    CrossrefPubMedSearch in Google Scholar
  • 41 Berlit P. Diagnosis and treatment of cerebral vasculitis. Ther Adv Neurol Disord 2010; 3: 29-42
    CrossrefPubMedSearch in Google Scholar
  • 42 Sakai K, Boche D, Carare R. et al. Aβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy. Acta Neuropathol 2014; 128: 777-789
    CrossrefPubMedSearch in Google Scholar
  • 43 Salloway S, Chalkias S, Barkhof F. et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol 2022; 79: 13-21
    CrossrefPubMedSearch in Google Scholar
  • 44 Klein G, Scelsi MA, Barakos J. et al. Comparing ARIA-E severity scales and effects of treatment management thresholds. Alzheimers Dement (Amst) 2022; 14: e12376
    CrossrefPubMedSearch in Google Scholar